Virtual Global Vaccine Summit, hosted by the UK government, to mobilise at least US$ 7.4 billion for Gavi’s mission to protect the next generation with vaccines, reduce disease inequality and create a healthier, safer and more prosperous world.
World leaders make historic commitments to provide equal access to vaccines for all.
London, 4 June 2020 – World leaders have pledged an additional US$ 8.8 billion for Gavi, the Vaccine Alliance, far exceeding the target of US$ 7.4 billion.
The funding will help immunise 300 million more children in the world’s poorest countries against diseases like measles, polio and diphtheria by the end of 2025. It will also support health systems to withstand the impact of coronavirus and maintain the infrastructure necessary to roll out a future COVID-19 vaccine on a global scale.
The pledges were made at the Global Vaccine Summit 2020, hosted by UK Prime Minister Boris Johnson. Representatives from 52 countries, including 35 Heads of State, joined leaders from global health organisations, the private sector, vaccine manufacturers and civil society organisations to support the Vaccine Alliance’s work protecting almost half the world’s children against deadly, preventable infectious diseases.
Gavi, the World Health Organization (WHO) and UNICEF have warned that 80 million children under the age of one are at risk of disease due to disruptions to vital immunisation programmes because of COVID-19.
The UK remains the Vaccine Alliance’s largest donor, pledging the equivalent of £330 million per year over the next five years. Other top donors include the Bill & Melinda Gates Foundation, Norway, Germany and the United States. Eight countries made their first ever pledge to Gavi, including Bhutan, Burkina Faso, Cameroon, Finland, Greece, New Zealand, Portugal and Uganda.
As well as supporting the routine vaccination of hundreds of millions of children in lower-income countries from infectious diseases, the new support will also be used to help lower-income countries meet the challenge of the coronavirus pandemic by strengthening health systems and vaccine distribution.
“Britain has been honoured to host this summit today,” said Boris Johnson, UK Prime Minister. “You can count on our full contribution as together we rise to fulfil the greatest shared endeavour of our lifetime - the triumph of humanity over disease, now and for the generations that follow. As we make the choice today to unite and forge a path of global co-operation, let us also renew our collective resolve to find the vaccine that can defeat coronavirus.”
“To beat the COVID-19 pandemic, the world needs more than breakthrough science. It needs breakthrough generosity. And that’s what we’re seeing today as leaders across the public and private sectors are stepping up to support Gavi – especially Prime Minister Johnson,” said Bill Gates, co-chair of the Bill & Melinda Gates Foundation. “When COVID-19 vaccines are ready, this funding and global coordination will ensure that people all over the world will be able to access them.”
Over the next five years, we will also see the largest investment in immunisation ever made by lower-income countries.
Gavi-supported countries will contribute US$ 3.6 billion towards the cost of buying vaccines – more than double the amount for the 2016-2020 period and more than 40% of the total estimated cost of supplying vaccines to these countries. They are also expected to invest around US$ 6 billion in immunisation service delivery costs over the same period. The dire economic effects of the COVID-19 pandemic may, however, disrupt these estimates.
Gavi’s market-shaping efforts to make life-saving vaccines more affordable have seen a 21% price reduction for fully immunising a child with pentavalent, pneumococcal and rotavirus vaccines – from $20.01 in 2015 to $15.90 in 2018.
“COVID-19 is a brutal reminder of why we must prioritise health,” said Roch Marc Christian Kaboré, President of Burkina Faso. “But if we fail to maintain the achievements we have made in vaccination, we risk the resurgence of deadly diseases like measles, yellow fever and polio. By working together to ensure the survival and prosperity of the people of Burkina Faso, of Africa and of the world, we will together write the most magnificent pages in our common history.”
Included in the total figure is US$ 0.9 billion in long-term pledges made to the innovative International Finance Facility for Immunisation (IFFIm), which will be used when needed to raise immediate funds on the capital markets.
“As the world battles against coronavirus, today’s UK-hosted Global Vaccine Summit has been a superb example of what we can achieve when we all take action together,” said Anne-Marie Trevelyan, UK International Development Secretary. “We know vaccines work, and I’m incredibly proud that we’ve exceeded Gavi’s pledging target to help protect 300 million more children from deadly illnesses through routine immunisation. This will help stop the spread of infection around the world, now, and in the future.”
The world’s biggest vaccine manufacturers also committed to continue supplying the billions of doses needed to continue increasing vaccine coverage across Africa and Asia. The Vaccine Alliance is one of the world’s largest and most successful public-private partnerships, and the wider private sector continued to show support for its mission with the announcement of more than US$ 70 million of new pledges and partnerships, bringing new technology, networks and expertise to help solve some of global health’s most intractable problems.
“On behalf of the countless vaccinators, supply chain workers, programme managers and the many, many others that work tirelessly every day to ensure children in vulnerable countries continue to receive lifesaving vaccines – thank you,” said Dr Ngozi Okonjo-Iweala, Gavi Board Chair. “We have made incredible progress over the past two decades improving vaccine coverage and reducing child mortality across Africa and Asia. This funding will give countries new hope that, despite the devastating impact of COVID-19, this progress can be sustained and built on. The Alliance will now get to work making this happen.”
The Global Vaccine Summit also saw the launch of the Advance Market Commitment for COVID-19 Vaccines (Covax AMC), a new innovative financing instrument to provide access to COVID-19 vaccines for low- and middle-income countries. This is the first building block towards a global mechanism to ensure equitable access to future COVID-19 vaccines. US$ 567 million was raised today in initial seed money for the AMC from 12 donors.
“As we celebrate a historic day we must also turn towards our next challenge: ensuring universal access to COVID-19 vaccines,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance. “One thing that has been made all too clear over the past few months is that this disease does not respect borders, which is why this global problem requires a global solution. After today’s success, we now need support to help ensure the most vulnerable people in low- and middle-income countries – as well as those in high- and upper middle-income countries – have access to COVID-19 vaccines.”
In addition to raising US$ 8.8 billion for Gavi’s 2021-25 period - the full list of pledges will be available soon - the Vaccine Summit also saw a number of new commitments and partnerships launched to support Gavi’s mission. These included:
Source - Gavi
Department of Biotechnology announces the scientific completion of India's first qHPV vaccine ‘CERVAVAC’
SII CEO Adar Poonawalla & Director Prakash Kumar Singh call on Hon'ble President of India Smt. Droupadi Murmu
Adar Poonawalla, CEO, Serum Institute of India, receives the award for the Outstanding Business Leader of the Year
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia
Serum Institute Of India sends out Covishield vaccine - Consignment of Covishield Vaccine arrived in Delhi, Chennai, Kolkata, Guwahati, Shillong, Ahmedabad, Hydrabad, Vijayawada, Bhubaneswar, Patna, Bengaluru, Lucknow, Chandigarh
Serum Institute of India launches India’s first fully indigenously developed pneumococcal vaccine, 'PNEUMOSIL'
Oxford COVID-19 vaccine: Serum Institute likely to submit final Covishield trial data within 10 days
SII’s Adar Poonawalla on Covid vaccine, pricing and rollout at Hindustan Times Leadership Summit 2020
COVISHIELD Completes Enrolment of Phase III clinical trials under partnership of ICMR and Serum Institute of India
Government Secures Vaccine Supplies For Half Of The Indian Population From Serum Institute And Novavax
IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
Serum Institute Of India Takes A Multipronged Approach In Quest To Produce World’s First Covid-19 Vaccines
Serum Institute of India to produce up to an additional 100 million covid 19 vaccine doses for india and low and midle income countries in 2021
Adar Poonawalla CEO of Serum Institute of India, the world’s largest vaccine manufacturer, explains the timing, challenges & cost of vaccinating the world against COVID-19
Serum Institute looking for a $1 billion shot to fight covid, talks on with Blackstone, KKR and others
Serum Institute of India Says Covid Vaccine Likely to Be Ready by End of 2020, Final Pricing in 2 Months
Serum institute of india to produce up to 100 million covid-19 vaccine doses for india and low-and middle-income countries as early as 2021
50% of our Covid vaccines will be for India, people won't have to buy them, govts will pay: Adar Poonawalla
AstraZeneca vaccine's success in early human trials, Will Begin AstraZeneca Vaccine Trial in India After Applying for Licence Next Week, Says Serum Institute
Serum Institute of India CEO: ‘We plan to make millions of doses of Covid vaccine over three months’:’
New supply agreement between UNICEF and Serum Institute of India makes pneumococcal conjugate vaccine available at US$2.00 per dose, a 43 % reduction from the Gavi price at the start of the Advance Market Commitment
Serum Institute confident of manufacturing Covid vaccine’s 100 million doses if trials establish efficacy
Serum Institute’s Journey To Success | ET NOW Covid-19 vaccine possible by Q2 of 2022: Adar Poonawalla
Adar Poonawalla discusses Serum Institute's progress in the global battle against COVID-19 with Shereen Bhan, CNBC-TV18
Adar Poonawalla talks with Aabha Bakaya about the success story of Serum Institute of India. Tune in to know all about the journey of the company.
Bill Gates confers Indian Council of Medical Research "Lifetime Achievement Medal" on Dr. Cyrus Poonawalla
Dr. Cyrus Poonawalla conferred with 'Lifetime Achievement Award’ by the Asian Business Leadership Forum
Dr. Cyrus Poonawalla conferred with the prestigious honorary degree by the University of Oxford, U.K.